BDM44768

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563479

CAS#: 2011754-00-8

Description: BDM44768 is an inhibitor of insulin-degrading enzyme (IDE) that cat by inducing glucose intolerance.


Price and Availability

Size
Price

Size
Price

Size
Price

BDM44768 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 563479
Name: BDM44768
CAS#: 2011754-00-8
Chemical Formula: C24H22FN5O3
Exact Mass: 447.1707
Molecular Weight: 447.47
Elemental Analysis: C, 64.42; H, 4.96; F, 4.25; N, 15.65; O, 10.73


Synonym: BDM44768; BDM-44768; BDM 44768;

IUPAC/Chemical Name: (S)-4-fluoro-N-((1-(4-(hydroxyamino)-1-(naphthalen-2-yl)-4-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)benzamide

InChi Key: RASCFMYPAZDCKQ-QFIPXVFZSA-N

InChi Code: InChI=1S/C24H22FN5O3/c25-20-9-7-18(8-10-20)24(32)26-14-21-15-30(29-27-21)22(13-23(31)28-33)12-16-5-6-17-3-1-2-4-19(17)11-16/h1-11,15,22,33H,12-14H2,(H,26,32)(H,28,31)/t22-/m0/s1

SMILES Code: O=C(NCC1=CN([C@@H](CC2=CC=C3C=CC=CC3=C2)CC(NO)=O)N=N1)C4=CC=C(F)C=C4


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


References

1: Salzano G, Wankar J, Ottani S, Villemagne B, Baulard AR, Willand N, Brodin P, Manet I, Gref R. Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs. Int J Pharm. 2017 Oct 15;531(2):577-587. doi: 10.1016/j.ijpharm.2017.05.030. Epub 2017 May 15. PubMed PMID: 28522424.

2: Deprez-Poulain R, Hennuyer N, Bosc D, Liang WG, Enée E, Marechal X, Charton J, Totobenazara J, Berte G, Jahklal J, Verdelet T, Dumont J, Dassonneville S, Woitrain E, Gauriot M, Paquet C, Duplan I, Hermant P, Cantrelle FX, Sevin E, Culot M, Landry V, Herledan A, Piveteau C, Lippens G, Leroux F, Tang WJ, van Endert P, Staels B, Deprez B. Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice. Nat Commun. 2015 Sep 23;6:8250. doi: 10.1038/ncomms9250. PubMed PMID: 26394692; PubMed Central PMCID: PMC4580987.